New research indicates that patients who come off popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional diet and exercise programs.
Findings released in a leading medical journal demonstrates that while obese individuals often shed a large proportion of their total mass while using the jabs, the mass returns at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing these drugs must be informed of the risk of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment mass within about 18 months.
Comparing Therapies
The analysis, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of these new drugs with older methods.
Scientists note that individuals who lose weight through dieting generally experience a slower creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Doctors believe the mechanism of the jabs explains the heightened weight return.
The injections imitate a natural hormone called GLP-1, which controls hunger.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means hunger is unsuppressed, making binge eating a significant risk."
A Lifelong Disease?
Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts argue that, considering the likelihood of weight regain, the therapy might need to be ongoing.
This view is echoed by pharmaceutical companies, who state that the results "emphasize the long-term nature of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Individuals who have stopped the jabs describe a sudden return of appetite.
"It was like a trigger that goes on and you're instantly extremely hungry," described an individual.
This challenge is exacerbated if patients have not developed lasting dietary or behavioural changes during therapy.
Growing Use
Figures show that millions of adults in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while the jabs are potent tools for shedding pounds, they are not a standalone solution and lasting health benefits hinges on combined behavioural changes.
